AP3329A - Acylated glucagon analogues - Google Patents

Acylated glucagon analogues

Info

Publication number: AP3329A
Authority: AP; ARIPO
Prior art keywords: glucagon analogues; acylated glucagon; acylated; analogues; glucagon
Prior art date: 2009-07-13

Application number

AP2012006107A

Other languages

English (en)

Other versions

AP2012006107A0 (en

Inventor

Ditte Riber

Marie Skovgaard

Eddi Meier

Original Assignee

Zealand Pharma As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-07-13

Filing date

2010-06-24

Publication date

2015-06-30

2010-06-24 Application filed by Zealand Pharma As filed Critical Zealand Pharma As

2012-02-29 Publication of AP2012006107A0 publication Critical patent/AP2012006107A0/xx

2015-06-30 Application granted granted Critical

2015-06-30 Publication of AP3329A publication Critical patent/AP3329A/xx

Links

MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Biophysics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AP2012006107A 2009-07-13 2010-06-24 Acylated glucagon analogues AP3329A (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US22508009P	2009-07-13	2009-07-13
EP09251780		2009-07-13
EP10157240		2010-03-22
DKPA201000412		2010-05-10
PCT/DK2010/000099 WO2011006497A1 (fr)	2009-07-13	2010-06-24	Analogues acylés du glucagon

Publications (2)

Publication Number	Publication Date
AP2012006107A0 AP2012006107A0 (en)	2012-02-29
AP3329A true AP3329A (en)	2015-06-30

Family

ID=43448959

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2012006107A AP3329A (en)	2009-07-13	2010-06-24	Acylated glucagon analogues

Country Status (29)

Country	Link
US (3)	US9156901B2 (fr)
EP (1)	EP2454282B1 (fr)
JP (1)	JP6054742B2 (fr)
KR (1)	KR101809024B1 (fr)
CN (2)	CN104961822A (fr)
AP (1)	AP3329A (fr)
AU (1)	AU2010272944B2 (fr)
CA (1)	CA2767792A1 (fr)
DK (1)	DK2454282T3 (fr)
EA (1)	EA022816B1 (fr)
EC (1)	ECSP12011593A (fr)
ES (1)	ES2537287T3 (fr)
GE (1)	GEP20146056B (fr)
HR (1)	HRP20150557T1 (fr)
HU (1)	HUE026255T2 (fr)
IL (1)	IL217150A0 (fr)
MA (1)	MA33517B1 (fr)
ME (1)	ME02220B (fr)
MX (1)	MX2012000564A (fr)
MY (1)	MY188182A (fr)
NZ (1)	NZ597981A (fr)
PE (1)	PE20121130A1 (fr)
PL (1)	PL2454282T3 (fr)
PT (1)	PT2454282E (fr)
RS (1)	RS53987B1 (fr)
SG (1)	SG177609A1 (fr)
SI (1)	SI2454282T1 (fr)
UA (1)	UA104766C2 (fr)
WO (1)	WO2011006497A1 (fr)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8642540B2 (en)	2008-12-15	2014-02-04	Zealand Pharma A/S	Glucagon analogues
ES2502218T3 (es)	2008-12-15	2014-10-03	Zealand Pharma A/S	Análogos de glucagón
MA32970B1 (fr)	2008-12-15	2012-01-02	Zealand Pharma As	Analogues du glucagon
AU2008365557A1 (en)	2008-12-15	2011-07-21	Zealand Pharma A/S	Glucagon analogues
JP6054742B2 (ja)	2009-07-13	2016-12-27	ジーランドファーマアクティーゼルスカブ	アシル化グルカゴン類似体
AR081975A1 (es)	2010-06-23	2012-10-31	Zealand Pharma As	Analogos de glucagon
CA2802897A1 (fr) *	2010-06-24	2011-12-29	Zealand Pharma A/S	Analogues de glucagon
EA201390796A1 (ru) *	2011-01-20	2014-07-30	Зилэнд Фарма А/С	Применение ацилированного аналога глюкагона
WO2012150503A2 (fr)	2011-05-03	2012-11-08	Zealand Pharma A/S	Composés sélectifs de la signalisation d'agoniste mixte glu-glp-1
WO2012153196A2 (fr)	2011-05-10	2012-11-15	Zealand Pharma A/S	Composés sélectifs pour une signalisation d'agonistes doubles de glu-glp1
HRP20181591T1 (hr)	2011-06-10	2018-11-30	Hanmi Science Co., Ltd.	Novi derivati oksintomodulina i farmaceutski pripravci za liječenje pretilosti koji ih sadrže
TWI601744B (zh)	2011-06-17	2017-10-11	韓美科學股份有限公司	包含調酸素與免疫球蛋白片段之複合物及其用途
MX354705B (es)	2011-09-23	2018-03-16	Novo Nordisk As	Analogos de glucagon novedosos.
KR20140114845A (ko) *	2011-12-23	2014-09-29	질랜드 파마 에이/에스	글루카곤 유사체
CA2872314C (fr)	2012-05-03	2021-08-31	Zealand Pharma A/S	Composes agonistes doubles du gip-glp-1 et methodes
EP2664374A1 (fr) *	2012-05-15	2013-11-20	F. Hoffmann-La Roche AG	Dérivés de dipeptide d'acide lysine-glutamique
JP2015525226A (ja)	2012-06-14	2015-09-03	サノフイ	エキセンディン−４ペプチドアナログ
NZ704043A (en) *	2012-07-23	2017-07-28	Zealand Pharma As	Glucagon analogues
KR101968344B1 (ko)	2012-07-25	2019-04-12	한미약품 주식회사	옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
AR092873A1 (es)	2012-09-26	2015-05-06	Cadila Healthcare Ltd	Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EA039082B1 (ru)	2012-11-06	2021-12-01	Ханми Фарм. Ко., Лтд.	Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина
KR101993393B1 (ko)	2012-11-06	2019-10-01	한미약품 주식회사	옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
WO2014081872A1 (fr)	2012-11-20	2014-05-30	Mederis Diabetes, Llc	Produits pharmaceutiques peptidiques améliorés pour la résistance à l'insuline
HUE035803T2 (en)	2012-12-21	2018-05-28	Sanofi Sa	Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
CA2902352A1 (fr) *	2013-03-14	2014-09-18	Medimmune Limited	Co-agonistes pegyles du glucagon et de glp-1 pour le traitement de l'obesite
US10450343B2 (en)	2013-03-21	2019-10-22	Sanofi-Aventis Deutschland Gmbh	Synthesis of cyclic imide containing peptide products
HUE034308T2 (en)	2013-03-21	2018-02-28	Sanofi Aventis Deutschland	Preparation of hydantoin-containing peptide products
AR095986A1 (es)	2013-04-03	2015-11-25	Sanofi Sa	Proteínas modificadas que regulan glucosa en sangre con perfil alterado de actividad farmacológica y preparación de las mismas
BR112015025464A2 (pt)	2013-04-18	2017-10-10	Novo Nordisk As	coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
GB201315335D0 (en)	2013-08-29	2013-10-09	Of Singapore	Amino diacids containing peptide modifiers
AR098065A1 (es)	2013-10-17	2016-04-27	Zealand Pharma As	Análogos de glucagón acilados
US9988429B2 (en) *	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
AU2014345570B2 (en)	2013-11-06	2019-01-24	Zealand Pharma A/S	Glucagon-GLP-1-GIP triple agonist compounds
CA2929459C (fr) *	2013-11-06	2022-05-03	Zealand Pharma A/S	Composes agonistes doubles de gip et glp-1 et procedes associes
TW201609797A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／升糖素受體促效劑
WO2015086730A1 (fr)	2013-12-13	2015-06-18	Sanofi	Analogues peptidiques de l'exendine 4 non acylés
WO2015086728A1 (fr)	2013-12-13	2015-06-18	Sanofi	Analogues peptidiques de l'exendine 4 en tant qu'agonistes mixtes des récepteurs glp-1/gip
WO2015086731A1 (fr)	2013-12-13	2015-06-18	Sanofi	Analogues peptidiques de l'exendine-4 en tant qu'agonistes mixtes des récepteurs glp-1/glucagon
EP3080154B1 (fr)	2013-12-13	2018-02-07	Sanofi	Agonistes doubles du récepteur glp-1/gip
AR098616A1 (es)	2013-12-18	2016-06-01	Lilly Co Eli	Péptido para el tratamiento de hipoglicemia severa
AR100306A1 (es)	2014-02-18	2016-09-28	Novo Nordisk As	Análogos de glucagón estables y uso para el tratamiento de la hipoglucemia
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
CN117582516A (zh)	2014-05-28	2024-02-23	梅德瑞斯糖尿病有限责任公司	针对胰岛素抵抗的改良肽药物
JP2017525656A (ja)	2014-06-04	2017-09-07	ノヴォノルディスクアー／エス	医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
TWI772252B (zh)	2014-09-16	2022-08-01	南韓商韓美藥品股份有限公司	長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
CN106519015B (zh) *	2014-09-23	2020-04-17	深圳市图微安创科技开发有限公司	胃泌酸调节素类似物
EP3212218B1 (fr)	2014-10-29	2021-06-30	Zealand Pharma A/S	Composés agonistes de gip et procédés associés
KR102291020B1 (ko)	2014-12-30	2021-08-20	한미약품 주식회사	안정성이 증가된 글루카곤 유도체
KR102418477B1 (ko)	2014-12-30	2022-07-08	한미약품 주식회사	글루카곤 유도체
UA121874C2 (uk)	2015-02-17	2020-08-10	Елі Ліллі Енд Компані	Порошкова назальна композиція для лікування гіпоглікемії
AR103954A1 (es)	2015-03-18	2017-06-14	Zealand Pharma As	Análogos de amilina
WO2016168388A2 (fr)	2015-04-14	2016-10-20	Palatin Technologies, Inc.	Thérapies pour l'obésité, le diabète et indications associées
PL3283507T3 (pl) *	2015-04-16	2020-05-18	Zealand Pharma A/S	Acylowany analog glukagonu
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198628A1 (fr)	2015-06-12	2016-12-15	Sanofi	Dérivés d'exendine-4 non-acylée comme agonistes doubles du récepteur glp -1/glucagon
WO2016198624A1 (fr)	2015-06-12	2016-12-15	Sanofi	Dérivés d'exendine 4 utilisés en tant qu'agonistes trigonaux des récepteurs du glp-1/glucagon/gip
FI3322437T3 (fi)	2015-06-30	2024-02-20	Hanmi Pharmaceutical Co Ltd	Glukagonijohdannainen ja sen pitkävaikutteisen konjugaatin käsittävä koostumus
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
TWI622596B (zh)	2015-10-26	2018-05-01	美國禮來大藥廠	升糖素受體促效劑
JP6712323B2 (ja)	2015-12-31	2020-06-17	ハンミファーマシューティカルカンパニーリミテッド	グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体
SG10202109721PA (en) *	2016-03-10	2021-10-28	Medimmune Ltd	Glucagon and glp-1 co-agonists for the treatment of obesity
CN106084031B (zh) *	2016-06-02	2020-03-31	中国药科大学	一类glp-1r/gcgr双重激动剂在用于降糖和减肥药物中的运用
CN105968186B (zh) *	2016-06-02	2020-10-30	中国药科大学	具有长效化作用的胰高血糖素(Glu)类似物及其应用
GB2566228A (en)	2016-06-09	2019-03-06	AmideBio LLC	Glucagon analogs and methods of use thereof
CN122440793A (zh)	2016-06-29	2026-07-24	韩美药品株式会社	胰高血糖素衍生物、其缀合物、包含其的组合物、和其治疗用途
AU2017307033B2 (en)	2016-08-05	2020-11-26	Boehringer Ingelheim International Gmbh	Oxadiazolopyridine derivates for use as ghrelin O-acyl transferase (GOAT) inhibitors
AR109514A1 (es)	2016-09-09	2018-12-19	Zealand Pharma As	Análogos de amilina
JOP20190095A1 (ar)	2016-10-27	2019-04-28	Janssen Pharmaceutica Nv	مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
AR110299A1 (es)	2016-12-02	2019-03-13	Sanofi Sa	Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
WO2018104558A1 (fr) *	2016-12-09	2018-06-14	Zealand Pharma A/S	Agonistes doubles de glp-1/glp-2 acylés
KR102502040B1 (ko) *	2016-12-09	2023-02-24	질랜드 파마 에이/에스	아실화 glp-1/glp-2 이중 효능제
AU2017373901B2 (en) *	2016-12-09	2021-06-03	Zealand Pharma A/S	GLP-1/GLP-2 dual agonists
CA3087925A1 (fr)	2018-02-02	2019-08-08	Boehringer Ingelheim International Gmbh	Derives de triazolopyrimidine destines a etre utilises en tant qu'inhibiteurs de la ghreline o-acyltransferase (goat)
CN111655699B (zh)	2018-02-02	2023-07-14	勃林格殷格翰国际有限公司	用作饥饿素o-酰基转移酶(goat)抑制剂的杂环基取代的噁二唑并吡啶衍生物
JP7225253B2 (ja)	2018-02-02	2023-02-20	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	グレリンｏ－アシルトランスフェラーゼ（ｇｏａｔ）阻害剤として使用するためのピラゾール置換及びインダゾール置換オキサジアゾロピリジン誘導体
MX2020008053A (es)	2018-02-02	2020-09-07	Boehringer Ingelheim Int	Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat).
CN110317258B (zh) *	2018-03-29	2023-03-17	齐鲁制药有限公司	一种索玛鲁肽的新多肽片段及其制备方法
US11780900B2 (en)	2018-04-25	2023-10-10	Janssen Sciences Ireland Unlimited Company	Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
US20220153853A1 (en)	2018-12-21	2022-05-19	Jiangsu Hengrui Medicine Co., Ltd.	Bispecific protein
TWI771669B (zh)	2019-04-26	2022-07-21	美商美國禮來大藥廠	製備穩定胜肽調配物之方法
KR20220100925A (ko)	2019-11-11	2022-07-18	베링거 인겔하임 인터내셔날 게엠베하	Npy2 수용체 작용제
EP4069726A4 (fr)	2019-12-04	2024-03-20	The Scripps Research Institute	Agonistes du récepteur glp2 et méthodes d'utilisation
WO2021233884A1 (fr)	2020-05-22	2021-11-25	Boehringer Ingelheim International Gmbh	Procédé continu de fabrication de 7-amino-5-méthyl-[1,2,5] oxadiazolo [3,4-b] pyridine-carboxylate d'alkyle
EP4153599B1 (fr)	2020-05-22	2024-03-13	Boehringer Ingelheim International GmbH	Procédé de fabrication de 7-amino-5-méthyl- [1,2,5] oxadiazolo [3,4-b] pyridine-carboxylate d'alkyle
WO2022029231A1 (fr)	2020-08-07	2022-02-10	Boehringer Ingelheim International Gmbh	Agonistes du récepteur npy2 solubles
AU2022289610A1 (en)	2021-06-09	2024-01-25	The Scripps Research Institute	Long-acting dual gip/glp-1 peptide conjugates and methods of use
IL312600B2 (en)	2022-05-30	2025-12-01	Zealand Pharma As	Liquid formulations of amylin analogs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008101017A2 (fr) *	2007-02-15	2008-08-21	Indiana Unversity Research And Technology Corporation	Co-agonistes des récepteurs du glucagon/glp-1
WO2010070251A1 (fr) *	2008-12-15	2010-06-24	Zealand Pharma A/S	Analogues du glucagon

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ202757A (en)	1981-12-23	1985-11-08	Novo Industri As	Peptides and medicaments
DE122009000079I2 (de)	1996-08-30	2011-06-16	Novo Nordisk As Novo Alle	Glp-1 derivate
EP0932614A1 (fr)	1996-09-09	1999-08-04	Zealand Pharmaceuticals A/S	Promedicaments peptidiques contenant une sequence de liaison alpha-hydroxyacide
CZ295838B6 (cs)	1996-09-09	2005-11-16	Zealand Pharma A/S	Způsob výroby peptidů
NZ504258A (en)	1997-11-14	2002-12-20	Amylin Pharmaceuticals Inc	Exendin 3 and 4 agonist compounds for the treatment of diabetes
AU757658B2 (en)	1998-03-09	2003-02-27	Zealand Pharma A/S	Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
EP1137667B1 (fr)	1998-12-07	2004-11-17	Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S.	Analogues du glp-1
US6451987B1 (en)	1999-03-15	2002-09-17	Novo Nordisk A/S	Ion exchange chromatography of proteins and peptides
CA2361830A1 (fr)	1999-03-17	2000-09-21	Novo Nordisk A/S	Methode d'acylation de peptides et nouveaux agents d'acylation
EP1076066A1 (fr)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides abaissant le taux de glucose sanguin
DE60137876D1 (de)	2000-06-16	2009-04-16	Lilly Co Eli	Analoge des Glucagon-ähnlichen Peptids-1
GB0121709D0 (en)	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
WO2003053460A1 (fr)	2001-12-19	2003-07-03	Eli Lilly And Company	Compositions cristallines pour reguler la glycemie
AU2002346490A1 (en)	2001-12-20	2003-07-09	Eli Lilly And Company	Insulin molecule having protracted time action
GB0300571D0 (en)	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
WO2004096854A2 (fr)	2003-04-29	2004-11-11	Eli Lilly And Company	Analogues de l'insuline ayant une action prolongee
RU2413530C9 (ru)	2004-11-12	2021-05-18	Ново Нордиск А/С	Стабильные препараты инсулинотропных пептидов
TWI362392B (en)	2005-03-18	2012-04-21	Novo Nordisk As	Acylated glp-1 compounds
CA2607566A1 (fr)	2005-05-06	2006-11-16	Bayer Pharmaceuticals Corporation	Agonistes vis-a-vis du recepteur peptidique de type glucagon 1 (glp-1) et procedes pharmacologiques d'utilisation
EP1891105B1 (fr)	2005-06-13	2012-04-11	Imperial Innovations Limited	Nouveaux composés et leurs effets sur le comportement alimentaire
US20090202497A1 (en)	2005-08-23	2009-08-13	The General Hospital Corporation	Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
CA2913805A1 (fr)	2005-11-07	2007-05-18	Indiana University Research And Technology Corporation	Analogues de glucagon a solubilite et a stabilite physiologiques ameliorees
US8343914B2 (en)	2006-01-06	2013-01-01	Case Western Reserve University	Fibrillation resistant proteins
EP2471810A1 (fr)	2006-02-22	2012-07-04	Merck Sharp & Dohme Corporation	Dérivés d'oxyntomoduline
ZA200900545B (en)	2006-07-18	2010-03-31	Sanofi Aventis	Antagonist antibody against EPHA2 for the treatment of cancer
ITMI20061607A1 (it)	2006-08-09	2008-02-10	Maria Vincenza Carriero	Peptidi con attivita farmacologica
EP2074140B8 (fr)	2006-10-04	2015-10-28	Case Western Reserve University	Insuline et analogues de l'insuline résistants à la fibrillation
TWI428346B (zh)	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
WO2008152403A1 (fr)	2007-06-15	2008-12-18	Zealand Pharma A/S	Analogues du glucagon
EP2025684A1 (fr)	2007-08-15	2009-02-18	Zealand Pharma A/S	Analogues du glucagon
CA2703830A1 (fr)	2007-11-20	2009-05-28	Ambrx, Inc.	Polypeptides d'insuline modifies et leurs utilisations
DE102008003568A1 (de)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003566A1 (de)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
KR20100111683A (ko)	2008-01-09	2010-10-15	사노피-아벤티스 도이칠란트 게엠베하	극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
RU2524423C2 (ru)	2008-01-09	2014-07-27	Санофи-Авентис Дойчланд Гмбх	Новые производные инсулина с чрезвычайно замедленным профилем время/действие
WO2009129250A2 (fr)	2008-04-14	2009-10-22	Case Western Reserve University	Analogues de l'insuline à prendre au moment des repas de stabilité améliorée
AU2009240636A1 (en)	2008-04-22	2009-10-29	Case Western Reserve University	Isoform-specific insulin analogues
TWI451876B (zh)	2008-06-13	2014-09-11	Lilly Co Eli	聚乙二醇化之離脯胰島素化合物
TWI541023B (zh)	2008-06-17	2016-07-11	印第安納大學科技研究公司	在生理ｐｈ緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物
ES2558842T3 (es)	2008-06-17	2016-02-09	Indiana University Research And Technology Corporation	Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad
CA2728284C (fr)	2008-06-17	2019-09-10	Richard D. Dimarchi	Co-agonistes du recepteur glucagon/glp-1
PL219335B1 (pl)	2008-07-04	2015-04-30	Inst Biotechnologii I Antybiotyków	Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
EP2318432B1 (fr)	2008-07-31	2015-09-02	Case Western Reserve University	Insuline stabilisée par de l'halogène
CA2732949C (fr)	2008-08-07	2016-12-20	Ipsen Pharma S.A.S.	Analogues de polypeptide insulinotrope glucose-dependant
CN102149411A (zh)	2008-09-12	2011-08-10	诺沃—诺迪斯克有限公司	酰化肽或蛋白的方法
US8642540B2 (en)	2008-12-15	2014-02-04	Zealand Pharma A/S	Glucagon analogues
ES2502218T3 (es)	2008-12-15	2014-10-03	Zealand Pharma A/S	Análogos de glucagón
AU2008365557A1 (en)	2008-12-15	2011-07-21	Zealand Pharma A/S	Glucagon analogues
US8697632B2 (en)	2008-12-19	2014-04-15	Indiana University Research And Technology Corporation	Amide based insulin prodrugs
JP5789515B2 (ja)	2008-12-19	2015-10-07	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	インスリン類似体
WO2010096052A1 (fr)	2009-02-19	2010-08-26	Merck Sharp & Dohme Corp.	Analogues d'oxyntomoduline
WO2010107487A2 (fr)	2009-03-18	2010-09-23	Wu Nian	Conjugués lipide-médicament pour administration de médicaments
CN101519446A (zh)	2009-03-31	2009-09-02	上海一就生物医药有限公司	一种重组人胰岛素及其类似物的制备方法
WO2010148089A1 (fr)	2009-06-16	2010-12-23	Indiana University Research And Technology Corporation	Composés de glucagon actifs sur le récepteur gip
JP6054742B2 (ja)	2009-07-13	2016-12-27	ジーランドファーマアクティーゼルスカブ	アシル化グルカゴン類似体
US20120329711A1 (en)	2009-12-16	2012-12-27	Nordisk A/S	Glp-1 receptor agonist compounds with a modified n-terminus
WO2011088837A1 (fr)	2010-01-20	2011-07-28	Zealand Pharma A/S	Traitement d'états pathologiques cardiaques
KR20120123443A (ko)	2010-01-27	2012-11-08	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
AR080592A1 (es)	2010-03-26	2012-04-18	Lilly Co Eli	Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
WO2011117417A1 (fr)	2010-03-26	2011-09-29	Novo Nordisk A/S	Nouveaux analogues de glucagon
WO2011134284A1 (fr)	2010-04-27	2011-11-03	浙江贝达药业有限公司	Analogue du glp-1 et ses applications
AR081975A1 (es)	2010-06-23	2012-10-31	Zealand Pharma As	Analogos de glucagon
CA2802897A1 (fr)	2010-06-24	2011-12-29	Zealand Pharma A/S	Analogues de glucagon
JP6231386B2 (ja)	2010-11-09	2017-11-15	ノヴォノルディスクアー／エス	リンカーを有する二重アシル化されたｇｌｐ−１誘導体
EA201390796A1 (ru)	2011-01-20	2014-07-30	Зилэнд Фарма А/С	Применение ацилированного аналога глюкагона
RU2013145013A (ru)	2011-03-28	2015-05-10	Ново Нордиск А/С	Новые аналоги глюкагона
AU2012241894B2 (en)	2011-04-12	2015-12-03	Novo Nordisk A/S	Double-acylated GLP-1 derivatives
WO2012150503A2 (fr)	2011-05-03	2012-11-08	Zealand Pharma A/S	Composés sélectifs de la signalisation d'agoniste mixte glu-glp-1
WO2012153196A2 (fr)	2011-05-10	2012-11-15	Zealand Pharma A/S	Composés sélectifs pour une signalisation d'agonistes doubles de glu-glp1
KR102002783B1 (ko)	2011-06-10	2019-07-24	베이징 한미 파마슈티컬 컴퍼니 리미티드	포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
MX354705B (es)	2011-09-23	2018-03-16	Novo Nordisk As	Analogos de glucagon novedosos.
KR20140114845A (ko)	2011-12-23	2014-09-29	질랜드 파마 에이/에스	글루카곤 유사체
CA2872314C (fr)	2012-05-03	2021-08-31	Zealand Pharma A/S	Composes agonistes doubles du gip-glp-1 et methodes
NZ704043A (en)	2012-07-23	2017-07-28	Zealand Pharma As	Glucagon analogues
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
AR098065A1 (es)	2013-10-17	2016-04-27	Zealand Pharma As	Análogos de glucagón acilados
CA2929459C (fr)	2013-11-06	2022-05-03	Zealand Pharma A/S	Composes agonistes doubles de gip et glp-1 et procedes associes
AR100306A1 (es)	2014-02-18	2016-09-28	Novo Nordisk As	Análogos de glucagón estables y uso para el tratamiento de la hipoglucemia
PL3283507T3 (pl)	2015-04-16	2020-05-18	Zealand Pharma A/S	Acylowany analog glukagonu

2010
- 2010-06-24 JP JP2012519884A patent/JP6054742B2/ja not_active Expired - Fee Related
- 2010-06-24 PE PE2012000038A patent/PE20121130A1/es not_active Application Discontinuation
- 2010-06-24 ES ES10737252.6T patent/ES2537287T3/es active Active
- 2010-06-24 SG SG2012002010A patent/SG177609A1/en unknown
- 2010-06-24 CN CN201510319285.XA patent/CN104961822A/zh active Pending
- 2010-06-24 WO PCT/DK2010/000099 patent/WO2011006497A1/fr not_active Ceased
- 2010-06-24 AP AP2012006107A patent/AP3329A/xx active
- 2010-06-24 AU AU2010272944A patent/AU2010272944B2/en not_active Ceased
- 2010-06-24 EP EP10737252.6A patent/EP2454282B1/fr active Active
- 2010-06-24 MY MYPI2012000113A patent/MY188182A/en unknown
- 2010-06-24 UA UAA201201419A patent/UA104766C2/uk unknown
- 2010-06-24 CA CA2767792A patent/CA2767792A1/fr not_active Abandoned
- 2010-06-24 GE GEAP201012567A patent/GEP20146056B/en unknown
- 2010-06-24 KR KR1020127003479A patent/KR101809024B1/ko not_active Expired - Fee Related
- 2010-06-24 HU HUE10737252A patent/HUE026255T2/en unknown
- 2010-06-24 DK DK10737252T patent/DK2454282T3/en active
- 2010-06-24 ME MEP-2015-72A patent/ME02220B/me unknown
- 2010-06-24 PT PT107372526T patent/PT2454282E/pt unknown
- 2010-06-24 CN CN201080038110.7A patent/CN102574903B/zh not_active Expired - Fee Related
- 2010-06-24 HR HRP20150557TT patent/HRP20150557T1/hr unknown
- 2010-06-24 EA EA201290027A patent/EA022816B1/ru not_active IP Right Cessation
- 2010-06-24 US US13/383,783 patent/US9156901B2/en not_active Expired - Fee Related
- 2010-06-24 MX MX2012000564A patent/MX2012000564A/es active IP Right Grant
- 2010-06-24 SI SI201030922T patent/SI2454282T1/sl unknown
- 2010-06-24 NZ NZ597981A patent/NZ597981A/en not_active IP Right Cessation
- 2010-06-24 RS RS20150326A patent/RS53987B1/sr unknown
- 2010-06-24 PL PL10737252T patent/PL2454282T3/pl unknown
2011
- 2011-12-22 IL IL217150A patent/IL217150A0/en unknown
2012
- 2012-01-11 EC EC2012011593A patent/ECSP12011593A/es unknown
- 2012-02-08 MA MA34615A patent/MA33517B1/fr unknown
2015
- 2015-09-02 US US14/843,047 patent/US10004786B2/en not_active Expired - Fee Related
2018
- 2018-05-22 US US15/985,934 patent/US20190076506A1/en not_active Abandoned

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008101017A2 (fr) *	2007-02-15	2008-08-21	Indiana Unversity Research And Technology Corporation	Co-agonistes des récepteurs du glucagon/glp-1
WO2010070251A1 (fr) *	2008-12-15	2010-06-24	Zealand Pharma A/S	Analogues du glucagon

Also Published As

Publication number	Publication date
GEP20146056B (en)	2014-03-10
PT2454282E (pt)	2015-06-23
US20190076506A1 (en)	2019-03-14
AP2012006107A0 (en)	2012-02-29
EP2454282B1 (fr)	2015-03-04
US20120178670A1 (en)	2012-07-12
HK1171035A1 (en)	2013-03-15
US9156901B2 (en)	2015-10-13
EP2454282A1 (fr)	2012-05-23
ME02220B (me)	2016-02-20
US20160120951A1 (en)	2016-05-05
HRP20150557T1 (xx)	2015-07-03
AU2010272944A1 (en)	2012-02-23
CN104961822A (zh)	2015-10-07
US10004786B2 (en)	2018-06-26
PE20121130A1 (es)	2012-08-30
EA022816B1 (ru)	2016-03-31
JP2012532898A (ja)	2012-12-20
MX2012000564A (es)	2012-04-11
RS53987B1 (sr)	2015-10-30
WO2011006497A1 (fr)	2011-01-20
IL217150A0 (en)	2012-02-29
AU2010272944B2 (en)	2015-11-19
CA2767792A1 (fr)	2011-01-20
ES2537287T3 (es)	2015-06-05
PL2454282T3 (pl)	2015-08-31
CN102574903B (zh)	2015-07-08
EA201290027A1 (ru)	2013-01-30
CN102574903A (zh)	2012-07-11
MA33517B1 (fr)	2012-08-01
SG177609A1 (en)	2012-02-28
UA104766C2 (uk)	2014-03-11
MY188182A (en)	2021-11-24
NZ597981A (en)	2014-02-28
HUE026255T2 (en)	2016-06-28
SI2454282T1 (sl)	2015-06-30
ECSP12011593A (es)	2012-02-29
KR101809024B1 (ko)	2017-12-14
KR20120052973A (ko)	2012-05-24
DK2454282T3 (en)	2015-05-04
JP6054742B2 (ja)	2016-12-27

Publication	Publication Date	Title
IL217150A0 (en)	2012-02-29	Acylated glucagon analogues
AP3286A (en)	2015-05-31	Glucagon analogues
IL213479A0 (en)	2011-07-31	Glucagon analogues
IL213478A0 (en)	2011-07-31	Glucagon analogues
IL213480A0 (en)	2011-07-31	Glucagon analogues
IL213477A0 (en)	2011-07-31	Glucagon analogues
AP2013006671A0 (en)	2013-01-31	Glucagon analogues
ZA201206838B (en)	2013-06-26	Novel glucagon analogues
DK3023438T3 (en)	2020-05-11	Anti-gitr-antistoffer
EP2443235A4 (fr)	2013-07-31	Variants de -glucosidase
ZA201201259B (en)	2013-08-28	Nitroimidazooxazine and nitroimidazooxazole analogues and their uses
EP2519921A4 (fr)	2014-03-26	Traçage d'appels
GB0920846D0 (en)	2010-01-13	Defenin inducing agent
TWM372017U (en)	2010-01-01	USB structure
GB0920831D0 (en)	2010-01-13	Clock
GB2468933B (en)	2011-03-23	Mechanical handless-faceless clock
GB2468953B (en)	2014-08-06	Freeze-cast components
AU4925P (en)	2014-09-22	Bonscawi Scaevola aemula
TWM386189U (en)	2010-08-11	Hanging-painting structure
TWM371036U (en)	2009-12-21	Doll-placing structure
ZA201008616B (en)	2011-10-26	Structure
TWM373647U (en)	2010-02-11	Insect-trapping structure
TWM371434U (en)	2010-01-01	Sun-hat structure
GB0920959D0 (en)	2010-01-13	ERoof structure
GB0711673D0 (en)	2007-07-25	Glucagon analogues